The goal of the Career Development Program of the Northwestern University-University of Chicago SPORE in Prostate Cancer is to recruit talented investigators to a career in translational prostate cancer research. In the current project period the SPORE Career Development Program (CDA) funded 7 CDA investigators from a pool of 20 applicants. These investigators were successful in obtaining 14 grant awards and they published 66 papers related to their CDA projects. The fact that the faculty come from a variety of departments has provided a source of diversity and scientific expertise to the investigators in the Program. Special efforts have been placed to emphasize the recruitment of women and minorities to the SPORE CDA. The Career Development Program has demonstrated flexibility in terms of offering awards and the length of the award. In the current funding period, the Prostate SPORE has maintained a consistent and highly structured process for advertisement of CDA positions, selection of CDA investigators and a good tracking system for monitoring and evaluating their progress. In the last SPORE submission, the CDA received an assessment of "Excellent". In this revised application, we have updated information of all CDA investigators and we again propose CDA funding for two investigators, one is to a woman (Hou) and the other is to a minority applicant (Posadas

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090386-10
Application #
8444308
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
10
Fiscal Year
2013
Total Cost
$165,422
Indirect Cost
$47,872
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Pascal, Laura E; Masoodi, Khalid Z; O'Malley, Katherine J et al. (2015) 5?-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. J Urol 193:1388-93
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Grin, Boris; Loeb, Stacy; Roehl, Kim et al. (2015) A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease. BJU Int 115:101-5
Helenowski, Irene B; Demirtas, Hakan (2014) Multiple imputation of continuous data via a semiparametric probability integral transformation. J Biopharm Stat 24:359-77
Venkatasubramanian, Palamadai N; Brendler, Charles B; Plunkett, Beth A et al. (2014) Periprostatic adipose tissue from obese prostate cancer patients promotes tumor and endothelial cell proliferation: a functional and MR imaging pilot study. Prostate 74:326-35
Adams, Daniel L; Martin, Stuart S; Alpaugh, R Katherine et al. (2014) Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A 111:3514-9
Ai, J; Pascal, L E; O'Malley, K J et al. (2014) Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model. Oncogene 33:2286-94
Pavese, Janet M; Ogden, Irene M; Voll, Eric A et al. (2014) Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis. PLoS One 9:e102289
Kregel, Steven; Szmulewitz, Russell Z; Vander Griend, Donald J (2014) The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate 74:1530-43
Wu, L; Runkle, C; Jin, H-J et al. (2014) CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor. Oncogene 33:504-13

Showing the most recent 10 out of 160 publications